CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000191" target="_blank" >RIV/26475821:_____/13:#0000191 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS

Popis výsledku v původním jazyce

Poster presenting clinical utility of molecular characterization of gastric cancer. According to the Czech national cancer register the prognosis of gastric cancer patients has remained unchanged over the course of the past 20 years. With a 5-year survival of just 30% (for all stages) it is the third most fatal malignancy of the gastrointestinal tract and sixth overall among solid cancers. The recent trends in discovery and use of biomarkers in other cancers have been mainly derived from detailed tumorprofiling. Somatic mutations and gene amplifications are among the molecular aberations frequently studied. The conclusion is: Somatic mutations are not associated with localization or stage and are likely not factors in prognosis of the disease. Molecular classification of gastric cancer based on gene amplification patterns results in distinct tumor similarities that may have clinical relevance for clinical management of gastric cancer.

Název v anglickém jazyce

CLINICAL UTILITY OF MOLECULAR CHARACTERIZATION OF GASTRIC CANCERS BASED ON SOMATIC MUTATIONS AND GENE AMPLIFICATIONS

Popis výsledku anglicky

Poster presenting clinical utility of molecular characterization of gastric cancer. According to the Czech national cancer register the prognosis of gastric cancer patients has remained unchanged over the course of the past 20 years. With a 5-year survival of just 30% (for all stages) it is the third most fatal malignancy of the gastrointestinal tract and sixth overall among solid cancers. The recent trends in discovery and use of biomarkers in other cancers have been mainly derived from detailed tumorprofiling. Somatic mutations and gene amplifications are among the molecular aberations frequently studied. The conclusion is: Somatic mutations are not associated with localization or stage and are likely not factors in prognosis of the disease. Molecular classification of gastric cancer based on gene amplification patterns results in distinct tumor similarities that may have clinical relevance for clinical management of gastric cancer.

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13640" target="_blank" >NT13640: Uplatnění panelu molekulárních markerů v klinickém managementu progredujícího karcinomu žaludku</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů